FMA
PPBT

FNY Managed Accounts’s Purple Biotech PPBT Stock Holding History

FNY Managed Accounts’s Portfolio PPBT Stock Details PPBT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-3
Closed -$17.4K – 210
2016
Q3 		$17.4K Buy
+3
New +$18.7K 0.01% 288

Other funds holding PPBT

MC
Menta Capital San Francisco, California $236M AUM 6.6% 1-Year Est. Return
AG
Advisor Group Phoenix, Arizona $14.5B AUM 24.86% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
MIFH
Migdal Insurance & Financial Holdings Petach Tikva, Israel $11.5B AUM 52.5% 1-Year Est. Return

FNY Managed Accounts's PPBT Position: Q4 2016 in Review

FNY Managed Accounts sold out of Purple Biotech (PPBT) in Q4 2016, closing a stake of 3 shares — an estimated $17.4K sold.

FNY Managed Accounts first reported a position in PPBT in Q3 2016 and held it in 1 quarter. The position peaked at $17.4K in Q3 2016. 6 funds tracked by Wall St. Rank hold PPBT as of Q4 2016.

  • FNY Managed Accounts reported no remaining Purple Biotech position as of Q4 2016 after selling out during the quarter.
  • FNY Managed Accounts sold 3 Purple Biotech shares in Q4 2016, an estimated $17.4K.
  • FNY Managed Accounts first reported a position in Purple Biotech in Q3 2016 and held it in 1 quarter.
  • FNY Managed Accounts's Purple Biotech position peaked at $17.4K in Q3 2016.
  • 6 funds tracked by Wall St. Rank held Purple Biotech as of Q4 2016.

Based on FNY Managed Accounts's 13F filing for Q4 2016, filed 8 Feb 2017.